Myrthe van Dijk, MD, UMC Utrecht, Utrecht, The Netherlands, presents results from the Phase II ESTIMATE trial (EudraCT 2019-003438-18), investigating the safety and efficacy of one-year fixed-dose mitapivat treatment in patients with sickle cell disease (SCD). The trial found improved hemoglobin levels compared to baseline and decreased markers of hemolysis, as well as showing mitapivat treatment to be well tolerated with low grade treatment-emergent adverse events (AEs). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
